<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537548</url>
  </required_header>
  <id_info>
    <org_study_id>4T-14-1</org_study_id>
    <secondary_id>NCI-2015-01177</secondary_id>
    <secondary_id>HS-15-00246</secondary_id>
    <secondary_id>4T-14-1</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT02537548</nct_id>
  </id_info>
  <brief_title>Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma</brief_title>
  <official_title>Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in
      treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in
      the body behind the intestines that is typically the first place that seminoma spreads. RPLND
      is a surgery that removes lymph nodes in this area to treat testicular seminoma and may
      experience fewer long-term toxicities, such as a second cancer, cardiovascular disease,
      metabolic syndrome (pre-diabetes), or lung disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the recurrence free survival (RFS) at 2 years after RPLND when RPLND is used as a
      first line treatment for patients with testicular seminoma and low volume (=&lt; 2cm)
      retroperitoneal disease.

      SECONDARY OBJECTIVES:

      I. Estimate the percent of patients, after treatment with RPLND, who can avoid external beam
      radiotherapy (XRT) or systemic chemotherapy (CTX) for seminoma.

      II. Assess the complications associated with primary RPLND for seminoma.

      OUTLINE:

      Patients undergo RPLND.

      After completion of study treatment, patients are followed up at 1 month, every 4 months for
      1 year, every 6 months for 2 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2015</start_date>
  <completion_date type="Anticipated">August 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RFS</measure>
    <time_frame>From RPLND to the time of recurrence or death, whichever comes first., assessed at 2 years after RPLND</time_frame>
    <description>Associated 95% confidence intervals will be constructed. Actuarial RFS will be calculated by the Kaplan Meier method. The recurrence location (pelvic, retroperitoneal, distant) will be calculated as a percentage of total recurrences to describe the clinical pattern of disease after relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term RPLND complication rates</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The rate of short and long term complications will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS</measure>
    <time_frame>From RPLND to the time of recurrence or death, whichever comes first., assessed at 5 years after RPLND</time_frame>
    <description>Associated 95% confidence intervals will be constructed. Actuarial RFS will be calculated by the Kaplan Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term RPLND complication rates</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The rate of short and long term complications will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Lymphadenopathy</condition>
  <condition>Stage I Testicular Seminoma</condition>
  <condition>Stage II Testicular Seminoma</condition>
  <arm_group>
    <arm_group_label>Treatment (RPLND)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo RPLND.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (RPLND)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retroperitoneal Lymph Node Dissection</intervention_name>
    <description>Undergo RPLND</description>
    <arm_group_label>Treatment (RPLND)</arm_group_label>
    <other_name>RPLND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pure seminoma after orchiectomy presenting with isolated retropreritoneal
             lymphadenopathy OR stage I pure seminoma with isolated retroperitoneal relapse.
             Relapse should be within 3 years

          -  Lymphadenopathy in the retroperitoneum: at least one lymph node 1-3 cm in greatest
             dimension, no lymph node &gt; 3 cm in greatest dimension, no more than 2 lymph nodes 1-3
             cm in greatest dimension

               -  Axial imaging of lymphadenopathy within 6 weeks of the date of RPLND

               -  Retroperitoneal lymphadenopathy must be within the RPLND template

          -  If there is borderline lymphadenopathy, defined as the largest retroperitoneal lymph
             node measuring 0.90 - 0.99 cm in the greatest dimension, an abdominal computed
             tomography (CT) scan should be repeated (recommend interval of 6 - 8 weeks); the same
             lymph node must demonstrate growth to &gt;= 1.0 cm in the greatest dimension

          -  Biopsy is not required, though if biopsy of the retroperitoneal node(s) was obtained,
             pathology must be consistent with pure seminoma

          -  Chest imaging (x-ray, CT or magnetic resonance imaging [MRI]) negative for metastasis
             no more than 6 weeks prior to the date of RPLND

          -  Primary tumor excised by radical inguinal orchiectomy and pathology consistent with
             pure seminoma

          -  Serum alpha fetoprotein (AFP) not more than 1.5 times upper limit of normal,
             beta-human chorionic gonadotropin (HCG), lactate dehydrogenase (LDH) (per the local
             laboratory assay) within 14 days of RPLND

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1

          -  Ability to understand and the willingness to sign a written informed consent

          -  Serum coagulation studies (INR/PTT) and platelet counts suitable for surgery per
             surgeon discretion.

        Exclusion Criteria:

          -  Second primary malignancy

          -  History of receiving chemotherapy or radiotherapy

          -  Patients receiving any other investigational agent (s)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siamak Daneshmand</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ileana Aldana</last_name>
    <phone>323-865-0702</phone>
    <email>Ileana.aldana@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tami Terry</last_name>
      <phone>909-558-7117</phone>
      <email>tterry@llu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Candace Turner-Santacroce</last_name>
      <phone>909-558-7113</phone>
      <email>cturner@llu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brian R Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldana Ileana</last_name>
      <phone>323-865-0702</phone>
      <email>ileana.aldana@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Siamak Daneshmand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emil B Lavaki</last_name>
      <phone>415-514-0554</phone>
      <email>emil.lavaki@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Maxwell V Meng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospitals &amp; Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ned Realiza</last_name>
      <phone>650-498-8496</phone>
      <email>nrealiza@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Fernando Serrano</last_name>
      <phone>650-724-3332</phone>
      <email>fserran2@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eila Skinner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camden Spade</last_name>
      <phone>404-778-4823</phone>
      <email>CSPADE@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Adouli</last_name>
      <phone>(404) 778-7397</phone>
    </contact_backup>
    <investigator>
      <last_name>Mehrdad Alemozaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Pulliam</last_name>
      <email>bpulliam@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Eggener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Dhondt</last_name>
      <phone>317-274-1791</phone>
      <email>cgerler@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Clint Cary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Wang, MS</last_name>
      <phone>410-502-2299</phone>
      <email>twang2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Phil Pierorazio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Smith, RN</last_name>
      <phone>507-266-8788</phone>
      <email>smith.jane2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steve Boorjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rugters Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903-2681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Karnicki</last_name>
      <phone>732-235-7771</phone>
      <email>cjk183@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Jang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center, University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Block, MS</last_name>
      <phone>405-271-8777</phone>
      <email>Ingrid-block@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly Stratton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UTSouthwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Beaver</last_name>
      <phone>214-645-8765</phone>
      <email>Allison.Beaver@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Doreen Simonsen</last_name>
      <phone>214-645-8790</phone>
      <email>Doreen.Simonsen@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aditya Bagrodia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seminoma</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

